Cytokinetics (CYTK) Misses Q1 EPS by 7c

Cytokinetics (NASDAQ: CYTK) reported Q1 EPS of ($0.54), $0.07 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $6.86 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Webull Corp (BULL) Tops Q2 EPS by 1c
• Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance